Cogent Biosciences, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Cogent Biosciences, Inc. now
Current reporting with the operating signal separated from the noise.
Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript
The story matters when it changes Cogent Biosciences, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript
The story matters when it changes Cogent Biosciences, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Cogent Biosciences, Inc. (COGT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Investors are testing whether Cogent Biosciences, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest COGT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Cogent Biosciences, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →